Bioptigen earns NIH grant for pediatric ophthalmology research

Ophthalmic imaging technology developer Bioptigen recently earned a $2.7 million, 27-month Phase II SBIR grant from the National Eye Institute of the U.S. National Institutes of Health (NIH).

Ophthalmic imaging technology developer Bioptigen (Durham, NC) recently earned a $2.7 million, 27-month Phase II SBIR grant from the National Eye Institute of the U.S. National Institutes of Health (NIH). The company will apply the grant to the research of spectral-domain optical coherence tomography (SD-OCT) systems targeted to the needs of the pediatric population.

The National Eye Institute grant was awarded for the investigation of technologies related to portable SD-OCT imaging that could be applied to the research, diagnosis and treatment of childhood eye diseases. The goal of this research would be to enable structural and functional imaging of premature and neonatal infants using a compact, handheld device.

The company's Envisu spectral-domain ophthalmic imaging platform employs low-power incoherent light to generate high-resolution, depth-resolved images of ocular tissues. The platform rapidly acquires and displays volumetric images suitable for real-time exploration of tissue physiology and pathology.

For more information, please visit www.bioptigen.com.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow OptoIQ on your iPhone; download the free app here.

Subscribe now to BioOptics World magazine; it's free!

More in Biophotonics Tools